Global Liquid Biopsy Market to 2028: Focus on Products and Services, Therapeutic Applications, Clinical Applications & Circulating Biomarkers - ResearchAndMarkets.com

October 10, 2018

DUBLIN--(BUSINESS WIRE)--Oct 10, 2018--The “Global Liquid Biopsy Market: Focus on Products and Services, Therapeutic Applications, Clinical Applications, Circulating Biomarkers, Country Analysis (16 Countries), Industry Insights, and Competitive Landscape - Analysis and Forecast, 2018-2028” report has been added to ResearchAndMarkets.com’s offering.

The global liquid biopsy market is anticipated to reach $2.94 billion by 2028, witnessing a CAGR of 14.45% in the forecast period 2018-2028.

The global liquid biopsy market has been witnessing a stable promising annual growth rate of 11.77% from the past three years (2014-2017). Some of the factors such as growing prominence for non-invasive diagnostic procedures, massive requirement of novel diagnostic techniques enabling treatment monitoring, and substantial investments made in the field of precision medicine and companion diagnostics are acting as significant factors propelling the growth of the global liquid biopsy market.

Currently, the liquid biopsy tests and services segment is the leading contributor to the global liquid biopsy market revenue. In 2017, the total market contribution of liquid biopsy tests and services was valued $344.8 million. The growing establishment of molecular diagnostics companies providing liquid biopsy tests with short turnaround times is bolstering the growth of the global liquid biopsy tests and services market. The global liquid biopsy market is currently dominated by products based on circulating tumor DNA (cTDNA). The contribution of the products based on circulating tumor DNA (cTDNA) was valued 45.00% of the total global liquid biopsy market revenue.

In terms of clinical application, the global liquid biopsy market is dominated by treatment monitoring. In 2017, the market for liquid biopsy products enabling treatment monitoring was valued $313.7 million. However, the growing prominence of companion diagnostics is anticipated to bolster the growth of the market for products enabling treatment selection. Currently, liquid biopsy is majorly incorporated for the treatment of lung cancer. The contribution of lung cancer liquid biopsy products was valued $186.9 million in 2017. In terms of regional potential, North America is the leading contributor to the global liquid biopsy market and is contributed approximately 55% of the global market values in 2017.

Currently, significant work is carried out to develop medical procedure based on liquid biopsy for the diagnosis of several diseases other than cancer. Through the detection of different biomarkers, the diagnosis of cardiovascular diseases, infections, and immunological and genetic disorders is certainly possible and opens new hopes for the patients. The development of test kits to diagnose aforementioned diseases appears to be a great opportunity to serve the market for both the new and the existing players.

Key Topics Covered:

Executive Summary

1 Market Overview

2 Market Dynamics

3 Competitive Insights

4 Industry Insights

5 Global Liquid Biopsy Market (by Circulating Biomarkers)

6 Global Liquid Biopsy Market (by Products)

7 Global Liquid Biopsy Market (by Therapeutic Application)

8 Global Liquid Biopsy Market (by Clinical Applications)

9 Global Liquid Biopsy Market (by Region)

10 Company Profiles

Abcodia Ltd. Adaptive Biotechnologies ANGLE plc Biocept, Inc. Bio-Rad Laboratories, Inc. Cynvenio Biosystems, Inc. Chronix Biomedical Epic Sciences, Inc. F. Hoffmann-La Roche AG GUARDANT HEALTH, INC Illumina, Inc. MDxHealth, Inc. Menarini Silicon Biosystems, Inc. Myriad Genetics, Inc. Natera, Inc. NeoGenomics Laboratories, Inc. Personal Genome Diagnostics, Inc. Qiagen N.V. Resolution Bioscience, Inc. Sysmex Corporation Thermo Fisher Scientific

For more information about this report visit https://www.researchandmarkets.com/research/4g32pn/global_liquid?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181010005657/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Biomarkers



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 10/10/2018 10:59 AM/DISC: 10/10/2018 10:59 AM


Update hourly